메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Medit Launches AuraVue: A Unified 3D Intraoral Scan and X-Ray Visualization Powered by Overjet AI

NEWPORT BEACH, Calif., Dec. 9, 2025 -- Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet's AI technology to deliver real-time diagnostic insights and clearer patient communication. With AuraVue, clinicians can now view 3D intraoral scans and X-rays side by side in one interactive workspace. By combining Medit's 3D imaging with Overjet's AI-powered radiographic analysis, AuraVue transforms diagnostic data into clear, visu
- 김갑성 기자
- 2025-12-09 21:30
AI CAD-OCI Integration Underway: ALL CONEC Begins Validation of Digital Prosthetic Data Workflow

SEOUL, South Korea, Dec. 9, 2025 -- ALL CONEC has been chosen as a participant in the Dream Venture Star 11 Oracle × Uclick Program and will begin validating a unified data workflow for digital prosthetic production. The initiative focuses on integrating design, fabrication, and inspection data—generated from ALL CONEC's AI CAD, ERP, 3D viewer, and IoT 3D printer solutions—into the Oracle Cloud Infrastructure (OCI) environment. In the current workflow, various data points created across stages of prosthetic production are often managed separately. ALL CONEC aims to store a
- 김갑성 기자
- 2025-12-09 19:55
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

SHANGHAI, Dec. 9, 2025 -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products con
- 김갑성 기자
- 2025-12-09 19:55
Dimora Medical Recognized as Key Driver in Winner Medical's Amazon Award

NEW YORK, Dec. 9, 2025 -- Winner Medical, the parent company of Dimora Medical, has been honored with the Paid Service Operation Excellence Award at the 2025 Amazon Global Selling Seller Conference, which focuses on excellence, innovation and global market. As one of Winner Medical's most influential international sub-brands, Dimora Medical played a pivotal role in this achievement, driven by its industry-leading performance in Amazon's wound-care category. "Several years ago, as we watched the advanced wound care market surge in Europe and North America, it became clear t
- 김갑성 기자
- 2025-12-09 18:35
ISLAND HOSPITAL NAMED MALAYSIA'S FIRST FLAGSHIP MEDICAL TOURISM HOSPITAL

GEORGETOWN, Malaysia, Dec. 9, 2025 -- Island Hospital is the winner of Malaysia's first Flagship Medical Tourism Hospital (FMTH) programme, a recognition of its consistent standards in care, safety and patient experience for international patients. Launched in 2022, the three-year programme aimed to identify hospitals that can anchor Malaysia's medical tourism growth globally. Island Hospital, selected as the top performer among four finalists, was the only hospital from Penang. The announcement was made today by Malaysia's Minister of Health, Yang Berhormat Datuk Seri Dr Dzulk
- 김갑성 기자
- 2025-12-09 18:18
Seven Zonta Clubs in Hong Kong unite to promote "Zonta Says NO to Violence Against Women" campaign and to support the Po Leung Kuk's mobile art exhibition "Violence? Love!!: A Voyage of Discovery"

HONG KONG, Dec. 9, 2025 -- The recent tragic fire at Tai Po has brought sadness and loss to our community. The seven Zonta Clubs in Hong Kong would like to express our deepest condolences to the victims and to extend our sympathy to all those affected. The swift response from all sectors of society reflects Hong Kong's spirit of helping each other during tough times, while also reminding us of the needs of vulnerable groups. According to the World Health Organization (WHO), violence against women and girls remains the most widespread and pervasive human rights violation globally, affec
- 김갑성 기자
- 2025-12-09 18:05
Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025

SHANGHAI, Dec. 9, 2025 -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK dual inhibitor, in B-cell lymphoma. Golidocitinib Newly diagnosed PTCL Two dose regimes of golidocitinib combined with CHOP have been explored for th
- 김갑성 기자
- 2025-12-09 18:00
VSure and HEYDOC Health Introduce CareConnect Suite, Transforming SME Protection and Digital Healthcare in Malaysia

KUALA LUMPUR, Malaysia, Dec. 9, 2025 -- In a move that reflects the shifting expectations of Malaysia's modern workforce, VSure Group and virtual healthcare provider HEYDOC Health have jointly launched CareConnect Suite, a new digital ecosystem aimed at closing long-standing gaps in employee benefits for small and medium enterprises (SMEs). The foundation of CareConnect Suite is the combination of EzPA — VSure's uniquely curated, affordable and accessible PA protection with hospital income benefit — and FutureK, HEYDOC Health's digitally integrated outpatient care model.
- 김갑성 기자
- 2025-12-09 15:58
Sweden Recommends: A Dose of Northern Lights Therapy

STOCKHOLM, Dec. 9, 2025 -- As the world's first country to be prescribed for its health benefits, Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy. The Swedish Prescription video shows how it works. With interest in "northern lights travel" on the rise and 61% of travelers naming the aurora borealis as the top natural phenomenon they want to experience, the timing couldn't be better. A rare solar maximum is underway, making aurora displays brighter, more frequent and
- 김갑성 기자
- 2025-12-09 15:53
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025

HONG KONG, Dec. 9, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as neoadjuvant therapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, was presented at the 2025 ESMO Asia Congress. Currently, Akeso is running the pivotal Phase III study (AK104-310/COMPASSION-33) investigating cadonilimab combined with the SOX regimen for perio
- 김갑성 기자
- 2025-12-09 15:50

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분